Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns

JACC. Advances · 2026 Oct 30 · Yan J, Zeng G et

By Maren Holt · Senior Reporter, GLP-1

Oct 29 20:00 ETSource: JACC. Advances

From the source

Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns
JACC. Advances · 2026 Oct 30 · Yan J, Zeng G et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42962433/